| 0.629 0.189 (42.95%) | 02-06 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 0.94 |
1-year : | 1.1 |
| Resists | First : | 0.81 |
Second : | 0.94 |
| Pivot price | 0.59  |
|||
| Supports | First : | 0.56 |
Second : | 0.41 |
| MAs | MA(5) : | 0.5 |
MA(20) : | 0.63 |
| MA(100) : | 1.66 |
MA(250) : | 2.49 |
|
| MACD | MACD : | -0.2 |
Signal : | -0.2 |
| %K %D | K(14,3) : | 25.7 |
D(3) : | 16.5 |
| RSI | RSI(14): 41.9 |
|||
| 52-week | High : | 4.76 | Low : | 0.41 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ HURA ] has closed below upper band by 44.5%. Bollinger Bands are 36.7% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 0.64 - 0.64 | 0.64 - 0.65 |
| Low: | 0.42 - 0.42 | 0.42 - 0.43 |
| Close: | 0.61 - 0.62 | 0.62 - 0.62 |
TuHURA Biosciences, Inc. is a phase 3 registration-stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. The company is headquartered in Tampa, FL.
Fri, 06 Feb 2026
FDA Grants Orphan Drug Status to Experimental Melanoma Therapy After Phase 1 Results - streetwisereports.com
Mon, 02 Feb 2026
FDA grants orphan status to TuHURA melanoma therapy IFx-2.0 - stocktitan.net
Mon, 02 Feb 2026
TuHURA Biosciences received FDA Orphan Drug Designation for IFx-2.0 for the Treatment of Stage IIB to Stage IV Cutaneous Melanoma - Sahm
Mon, 15 Dec 2025
TuHURA Biosciences (NASDAQ: HURA) to issue 1.54M shares after REM-001 CVR milestone - stocktitan.net
Thu, 11 Dec 2025
TuHURA Biosciences (NASDAQ: HURA) outlines 2026 trial milestones after $15.6M raise - stocktitan.net
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 56 (M) |
| Shares Float | 32 (M) |
| Held by Insiders | 30.1 (%) |
| Held by Institutions | 10 (%) |
| Shares Short | 2,990 (K) |
| Shares Short P.Month | 3,070 (K) |
| EPS | -0.71 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.31 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -60.2 % |
| Return on Equity (ttm) | -418.1 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -0.45 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -25 (M) |
| Levered Free Cash Flow | -1 (M) |
| PE Ratio | -0.87 |
| PEG Ratio | 0 |
| Price to Book value | 1.92 |
| Price to Sales | 0 |
| Price to Cash Flow | -1.42 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|